search
Back to results

Adherence to Lifestyle Changes for Age-related Macular Degeneration (AMD-Life)

Primary Purpose

Age-Related Macular Degeneration

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Standard lifestyle recommendations + dietary supplementation
Risk profiling
Coaching
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Age-Related Macular Degeneration focused on measuring Age-Related Macular Degeneration, Lifestyle, Lifestyle change, Genetic testing, Personalized risk-profiling, Gut microbiome, Coaching

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Early/Intermediate AMD or unilateral late AMD with minimal vision 0.8 Exclusion Criteria: Participation in other intervention studies for AMD Living in retirement homes (difficulty in implementation of diet) Diagnosis of dementia (because of unreliable dietary recall) Persons with macular pathology other than AMD hindering appropriate grading of the macula Persons who are illiterate and have no independent trusted person with them to explain the informed consent form. Persons diagnosed with liver and kidney insufficiency.

Sites / Locations

  • Erasmus Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Standard recommendations

Standard recommendations + Risk profiling

Standard recommendations + Risk profiling + Additional coaching

Arm Description

The first group (n=50) will receive standard care recommendations (according to Netherlands Scientific Society of Ophthalmology 2014, 'Richtlijn Leeftijdsgebonden Maculadegeneratie;): refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish; and recommendations for supplementation with antioxidants according an established formula.

The second group (n=50) receives standard care plus personalized risk profiling. A risk scoring based on currently available literature for lifestyle and genetic risk will be used to determine personalized risks of conversion to late AMD. Individuals will be informed about their own risk profile and a personalized strategy will be communicated.

The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.

Outcomes

Primary Outcome Measures

Change in lifestyle score
Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle
Change in lifestyle score
Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle

Secondary Outcome Measures

Full Information

First Posted
November 21, 2022
Last Updated
December 19, 2022
Sponsor
Erasmus Medical Center
Collaborators
CORR foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05667441
Brief Title
Adherence to Lifestyle Changes for Age-related Macular Degeneration
Acronym
AMD-Life
Official Title
Adherence to Lifestyle Changes for Age-related Macular Degeneration
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2021 (Actual)
Primary Completion Date
August 1, 2025 (Anticipated)
Study Completion Date
August 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
Collaborators
CORR foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The AMD-Life study investigates which strategies (personalized risk-profiling including genetic testing and/or coaching) motivate AMD patients to change their lifestyle.
Detailed Description
Age-related macular degeneration is a frequent eye disease in the elderly affecting the center of retina, i.e., the macula. Despite current treatments for the wet form of this disease, it is still the most frequent cause of blindness in the Western world. The disease is the result of the interplay between genetic and environmental factors such as smoking, unhealthy diet, and lack of physical activity. The current clinical recommendations are aimed towards these lifestyle factors: a healthy diet, no smoking, regular physical exercise, and use of antioxidant supplementation. Although assumed to be low by clinicians as they feel patients find it difficult to actually alter their lifestyle, the adherence and feasibility to these recommendations in clinical ophthalmology practice is unclear. Individualizing the patients' risk of blindness and lifestyle changes, as well as coaching may positively influence adherence strategies. This pilot study aims to gain knowledge and experience in a relatively small study comparing adherence to these strategies through a healthier lifestyle. Additionally, the trial investigates blood and gut microbiome biomarkers: which molecules in blood directly relate to the supplemented nutrients as well as those related to the pathogenesis of AMD, and which biomarkers in blood and eye best correlate with supplement intake and lifestyle.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Macular Degeneration
Keywords
Age-Related Macular Degeneration, Lifestyle, Lifestyle change, Genetic testing, Personalized risk-profiling, Gut microbiome, Coaching

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label, randomized, clinical trial with 3 arms. Total study duration 2 years: intervention period for 1 year and a follow-up period of 1 year with no intervention for all study arms.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard recommendations
Arm Type
Active Comparator
Arm Description
The first group (n=50) will receive standard care recommendations (according to Netherlands Scientific Society of Ophthalmology 2014, 'Richtlijn Leeftijdsgebonden Maculadegeneratie;): refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish; and recommendations for supplementation with antioxidants according an established formula.
Arm Title
Standard recommendations + Risk profiling
Arm Type
Active Comparator
Arm Description
The second group (n=50) receives standard care plus personalized risk profiling. A risk scoring based on currently available literature for lifestyle and genetic risk will be used to determine personalized risks of conversion to late AMD. Individuals will be informed about their own risk profile and a personalized strategy will be communicated.
Arm Title
Standard recommendations + Risk profiling + Additional coaching
Arm Type
Active Comparator
Arm Description
The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.
Intervention Type
Combination Product
Intervention Name(s)
Standard lifestyle recommendations + dietary supplementation
Intervention Description
refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
Intervention Type
Combination Product
Intervention Name(s)
Risk profiling
Intervention Description
Personalized risk profiling for lifestyle and genetics.
Intervention Type
Behavioral
Intervention Name(s)
Coaching
Intervention Description
Coaching
Primary Outcome Measure Information:
Title
Change in lifestyle score
Description
Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle
Time Frame
0 and 12 months: intervention phase
Title
Change in lifestyle score
Description
Change in lifestyle as measured by online questionnaires, scale from 0-13 in which 13 represents a healthy lifestyle
Time Frame
12 and 24 months: follow-up phase

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Early/Intermediate AMD or unilateral late AMD with minimal vision 0.8 Exclusion Criteria: Participation in other intervention studies for AMD Living in retirement homes (difficulty in implementation of diet) Diagnosis of dementia (because of unreliable dietary recall) Persons with macular pathology other than AMD hindering appropriate grading of the macula Persons who are illiterate and have no independent trusted person with them to explain the informed consent form. Persons diagnosed with liver and kidney insufficiency.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Magda Meester, Dr
Phone
+31107040704
Email
amd.life@erasmusmc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
C.C.W. Klaver, Prof. Dr.
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Erasmus Medical Center
City
Rotterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Magda Meester, Dr
Phone
+31107040704
Email
amd.life@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Sheila de Koning-Backus, MSc
Phone
+31107040704
Email
amd.life@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
C.C.W. Klaver, Prof.dr.

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://www.maculadegeneratie.nl
Description
AMD-Life website with information for potential participants

Learn more about this trial

Adherence to Lifestyle Changes for Age-related Macular Degeneration

We'll reach out to this number within 24 hrs